Free Trial
→ New Federal Land Rush About to Start? (From Stansberry Research) (Ad) Free ABBV Stock Alerts

AbbVie (ABBV) Financials

AbbVie logo
$195.17 +6.15 (+3.25%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$195.10 -0.07 (-0.04%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AbbVie

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 5,144 5,953 5,309 5,687 7,882 4,616 11,542 11,836 4,863 4,278
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Total Pre-Tax Income 		6,645 7,884 7,727 5,197 8,426 3,398 12,989 13,477 6,250 3,716
Total Operating Income		 7,537 9,340 9,545 6,383 12,983 11,363 17,924 18,117 12,757 9,137
Total Gross Profit		 18,359 19,806 21,174 25,035 25,827 29,041 38,751 39,943 33,125 39,430
Total Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334
Operating Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334
Total Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 21,193 16,904
Operating Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 21,193 16,904
Total Operating Expenses		 10,822 10,466 11,629 18,652 12,844 17,678 20,827 21,826 20,368 30,293
Selling, General & Admin Expense		 6,387 5,881 6,295 7,399 6,942 11,299 13,473 15,260 12,872 17,509
Research & Development Expense		 4,435 4,585 5,334 10,753 6,792 6,379 6,922 6,510 7,675 12,791
Other Operating Expenses / (Income)		 - - 0.00 500 -890 0.00 432 56 -179 -7.00
Total Other Income / (Expense), net		 -892 -1,456 -1,818 -1,186 -4,557 -7,965 -4,935 -4,640 -6,507 -5,421
Interest & Investment Income		 -686 -965 -1,004 -1,144 -1,509 -2,280 -2,384 -2,044 -1,684 -2,160
Other Income / (Expense), net		 -206 -491 -814 -42 -3,048 -5,685 -2,551 -2,596 -4,823 -3,261
Income Tax Expense		 1,501 1,931 2,418 -490 544 -1,224 1,440 1,632 1,377 -570
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 0.00 6.00 7.00 9.00 10 8.00
Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40
Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39
Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.63B 1.63B 1.60B 1.55B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B

Quarterly Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 924 3,949 2,473 239 2,024 1,778 822 1,369 1,370 1,561 -22
Consolidated Net Income / (Loss)		 928 3,952 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23
Net Income / (Loss) Continuing Operations		 928 3,952 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23
Total Pre-Tax Income 		1,183 4,400 2,965 475 2,610 1,953 1,212 1,755 2,146 2,084 -2,269
Total Operating Income		 3,295 4,603 5,502 2,768 4,513 2,281 3,195 2,798 3,998 3,831 -1,490
Total Gross Profit		 10,144 9,750 10,708 8,089 9,625 7,376 8,035 8,052 9,323 10,248 11,807
Total Revenue		 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 14,462 14,460 15,102
Operating Revenue		 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 14,462 14,460 15,102
Total Cost of Revenue		 4,439 5,062 4,413 4,136 4,240 6,551 6,266 4,258 5,139 4,212 3,295
Operating Cost of Revenue		 4,439 5,062 4,413 4,136 4,240 6,551 6,266 4,258 5,139 4,212 3,295
Total Operating Expenses		 6,849 5,147 5,206 5,321 5,112 5,095 4,840 5,254 5,325 6,417 13,297
Selling, General & Admin Expense		 5,412 3,304 3,417 3,039 3,548 3,372 2,913 3,315 3,377 4,287 6,530
Research & Development Expense		 1,609 1,614 1,790 2,292 1,733 1,723 1,927 1,939 1,948 2,130 6,774
Other Operating Expenses / (Income)		 -172 229 -1.00 -10 -169 0.00 - 0.00 0.00 0.00 -7.00
Total Other Income / (Expense), net		 -2,112 -203 -2,537 -2,293 -1,903 -328 -1,983 -1,043 -1,852 -1,747 -779
Interest & Investment Income		 -532 -497 -476 -454 -454 -398 -378 -453 -506 -591 -610
Other Income / (Expense), net		 -1,580 294 -2,061 -1,839 -1,449 70 -1,605 -590 -1,346 -1,156 -169
Income Tax Expense		 255 448 493 234 583 172 388 383 773 520 -2,246
Net Income / (Loss) Attributable to Noncontrolling Interest		 4.00 3.00 -1.00 2.00 3.00 3.00 2.00 3.00 3.00 3.00 -1.00
Basic Earnings per Share		 $0.52 $2.22 $1.39 $0.13 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02)
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $0.51 $2.21 $1.40 $0.13 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03)
Weighted Average Diluted Shares Outstanding		 1.78B 1.78B 1.78B 1.78B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.76B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B

Annual Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 51 -3,299 4,203 -2,014 32,635 -31,475 1,297 -545 3,613 -7,290
Net Cash From Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806
Net Cash From Continuing Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286
Depreciation Expense		 417 425 425 471 464 666 803 778 752 764
Amortization Expense		 419 764 1,076 1,294 1,553 5,805 7,718 7,689 7,946 7,622
Non-Cash Adjustments To Reconcile Net Income		 1,051 1,360 2,515 7,052 1,663 2,961 2,157 3,895 4,216 6,594
Changes in Operating Assets and Liabilities, net		 504 -1,461 635 -1,077 1,762 3,534 550 736 5,052 -460
Net Cash From Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820
Net Cash From Continuing Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820
Purchase of Property, Plant & Equipment		 -532 -479 -529 -638 -552 -798 -787 -695 -777 -974
Acquisitions		 -11,488 -2,495 - 0.00 0.00 -38,260 -525 -255 0.00 -17,493
Purchase of Investments		 -1,815 -5,577 -2,538 -2,528 -1,718 -1,411 -1,496 -1,977 -1,300 -3,097
Sale and/or Maturity of Investments		 899 2,359 2,793 2,160 2,699 1,525 98 1,530 55 555
Other Investing Activities, net		 0.00 118 0.00 0.00 167 1,387 366 774 13 189
Net Cash From Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211
Net Cash From Continuing Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211
Repayment of Debt		 -4,018 -6,010 -25 -6,035 -4,501 -5,675 -9,390 -14,403 -4,101 -14,564
Repurchase of Common Equity		 -7,768 -6,102 -1,410 -12,054 -1,053 -998 -934 -1,487 -2,010 -1,807
Payment of Dividends		 -3,294 -3,717 -4,107 -5,580 -6,366 -7,716 -9,261 -10,043 -10,539 -11,025
Issuance of Debt		 20,696 11,633 44 9,278 30,783 3,000 1,000 2,000 0.00 21,971
Other Financing Activities, net		 155 268 -14 -5.00 -155 -112 -454 -870 -572 214
Effect of Exchange Rate Changes		 - -338 29 -39 7.00 -5.00 -97 -62 5.00 -65
Cash Interest Paid		 536 986 1,099 1,215 1,794 2,619 2,712 2,546 2,469 2,811
Cash Income Taxes Paid		 1,108 3,563 1,696 0.00 1,447 1,674 3,648 2,988 4,702 4,064

Quarterly Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 2,423 3,311 -2,631 -2,490 2,048 4,528 -473 5,253 -4,937 -5,873 -1,733
Net Cash From Operating Activities		 5,005 7,602 7,428 4,193 6,319 7,574 4,753 4,040 2,271 5,447 7,048
Net Cash From Continuing Operating Activities		 5,005 7,602 7,428 4,193 6,319 7,574 4,753 4,040 2,271 5,447 7,048
Net Income / (Loss) Continuing Operations		 928 3,952 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23
Consolidated Net Income / (Loss)		 928 3,952 2,472 241 2,027 1,781 824 1,372 1,373 1,564 -23
Depreciation Expense		 203 181 196 179 190 196 187 183 184 191 206
Amortization Expense		 1,849 2,024 1,961 1,948 2,070 2,039 1,889 1,891 1,947 1,888 1,896
Non-Cash Adjustments To Reconcile Net Income		 2,180 781 355 1,031 294 1,786 1,105 76 689 -25 5,854
Changes in Operating Assets and Liabilities, net		 -155 664 2,444 794 1,738 1,772 748 518 -1,922 1,829 -885
Net Cash From Investing Activities		 130 1,286 -448 -499 -341 -369 -800 -9,588 -1,102 -8,256 -1,874
Net Cash From Continuing Investing Activities		 130 1,286 -448 -499 -341 -369 -800 -9,588 -1,102 -8,256 -1,874
Purchase of Property, Plant & Equipment		 -143 -177 -213 -175 -178 -219 -205 -193 -241 -249 -291
Purchase of Investments		 -214 -117 -55 -372 -176 -165 -587 -196 -859 -223 -1,819
Sale and/or Maturity of Investments		 42 1,410 70 22 14 5.00 14 6.00 3.00 507 39
Other Investing Activities, net		 445 170 5.00 26 -1.00 10 -22 -6.00 -5.00 3.00 197
Net Cash From Financing Activities		 -2,679 -5,518 -9,634 -6,192 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861
Net Cash From Continuing Financing Activities		 -2,679 -5,518 -9,634 -6,192 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861
Repayment of Debt		 3.00 -2,686 -6,862 -1,330 -1,003 28 -1,796 -5,183 -3,348 -371 -5,662
Repurchase of Common Equity		 -9.00 -4.00 -4.00 -1,955 -10 -4.00 -41 -1,324 -9.00 -17 -457
Payment of Dividends		 -2,507 -2,504 -2,506 -2,661 -2,625 -2,627 -2,626 -2,772 -2,750 -2,751 -2,752
Issuance of Debt		 - - - 0.00 - - - 19,971 - - 2,000
Other Financing Activities, net		 -166 -324 -262 -246 -282 -58 14 127 10 67 10
Effect of Exchange Rate Changes		 -33 -59 23 8.00 -10 -16 23 -18 -9.00 8.00 -46

Annual Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161
Total Current Assets		 16,314 16,187 21,223 16,945 49,519 24,173 27,928 28,463 33,002 25,582
Cash & Equivalents		 8,399 5,100 9,303 7,289 39,924 8,449 9,746 9,201 12,814 5,524
Short-Term Investments		 8.00 1,323 486 772 0.00 30 84 28 2.00 31
Accounts Receivable		 4,730 4,758 5,088 5,384 5,428 8,822 9,977 11,254 11,155 10,919
Inventories, net		 1,719 1,444 1,605 1,605 1,813 3,310 3,128 3,579 4,099 4,181
Prepaid Expenses		 1,458 3,562 4,741 1,895 2,354 3,562 4,993 4,401 4,932 4,927
Plant, Property, & Equipment, net		 2,565 2,604 2,803 2,883 2,962 5,248 5,110 4,935 4,989 5,134
Total Noncurrent Assets		 34,171 47,308 46,760 39,524 36,634 121,144 113,491 105,407 96,720 104,445
Long-Term Investments		 145 1,783 2,090 1,420 93 293 277 241 304 279
Goodwill		 13,168 15,416 15,785 15,663 15,604 33,124 32,379 32,156 32,293 34,956
Intangible Assets		 19,709 28,897 27,559 21,233 18,649 82,876 75,951 67,439 55,610 60,068
Other Noncurrent Operating Assets		 1,149 1,212 1,326 1,208 2,288 4,851 4,884 5,571 8,513 9,142
Total Liabilities & Shareholders' Equity		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161
Total Liabilities		 49,105 61,463 65,689 67,798 97,287 137,468 131,093 121,518 124,314 131,797
Total Current Liabilities		 10,894 9,781 16,641 17,239 15,585 28,661 35,194 29,538 37,841 38,749
Short-Term Debt		 2,431 402 6,415 5,308 3,753 8,502 12,495 4,136 7,191 6,804
Accounts Payable		 8,463 9,379 10,226 11,931 11,832 20,159 22,699 25,402 30,650 31,945
Total Noncurrent Liabilities		 38,211 51,682 49,048 50,559 81,702 108,807 95,899 91,980 86,473 93,048
Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340
Noncurrent Deferred & Payable Income Tax Liabilities		 5,276 6,890 2,490 1,067 1,130 3,646 3,009 2,190 1,952 2,579
Other Noncurrent Operating Liabilities		 - - - - 17,597 27,607 28,701 30,655 32,327 30,129
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,945 4,636 5,097 -8,446 -8,172 13,097 15,436 17,287 10,397 3,364
Total Preferred & Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325
Total Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325
Common Stock		 13,097 13,696 14,288 14,774 15,211 17,402 18,323 19,263 20,198 21,351
Retained Earnings		 2,248 4,378 5,459 3,368 4,717 1,055 3,127 4,784 -1,000 -7,900
Treasury Stock		 -8,839 -10,852 -11,923 -24,108 -24,504 -2,264 -3,143 -4,594 -6,533 -8,201
Accumulated Other Comprehensive Income / (Loss)		 -2,561 -2,586 -2,727 -2,480 -3,596 -3,117 -2,899 -2,199 -2,305 -1,925
Noncontrolling Interest		 - - - - 0.00 21 28 33 37 39

Quarterly Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Total Assets		 143,186 141,325 138,805 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161
Total Current Assets		 29,100 30,364 28,463 26,488 28,852 33,224 33,002 38,871 33,816 27,785 25,582
Cash & Equivalents		 8,521 11,832 9,201 6,711 8,759 13,287 12,814 18,067 13,130 7,257 5,524
Short-Term Investments		 1,440 47 28 11 7.00 3.00 2.00 2.00 27 28 31
Accounts Receivable		 11,237 10,743 11,254 11,473 11,491 11,412 11,155 11,949 11,724 11,472 10,919
Inventories, net		 3,396 3,172 3,579 3,833 4,055 3,981 4,099 4,245 4,218 4,450 4,181
Prepaid Expenses		 4,506 4,570 4,401 4,460 4,540 4,541 4,932 4,608 4,717 4,578 4,927
Plant, Property, & Equipment, net		 4,958 4,893 4,935 4,931 4,943 4,934 4,989 4,980 5,023 5,141 5,134
Total Noncurrent Assets		 109,128 106,068 105,407 103,125 101,572 98,063 96,720 105,023 103,098 110,496 104,445
Long-Term Investments		 244 235 241 257 288 275 304 305 272 267 279
Goodwill		 32,028 31,726 32,156 32,220 32,224 32,091 32,293 33,426 33,386 35,295 34,956
Intangible Assets		 71,823 68,725 67,439 64,848 62,862 58,603 55,610 62,225 60,243 66,646 60,068
Other Noncurrent Operating Assets		 5,033 5,382 5,571 5,800 6,198 7,094 8,513 9,067 9,197 8,288 9,142
Total Liabilities & Shareholders' Equity		 143,186 141,325 138,805 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161
Total Liabilities		 128,498 125,298 121,518 121,241 122,469 124,092 124,314 140,827 135,116 137,351 131,797
Total Current Liabilities		 34,473 32,712 29,538 27,590 32,239 34,773 37,841 41,522 41,915 43,062 38,749
Short-Term Debt		 11,930 9,207 4,136 2,801 5,203 5,115 7,191 10,196 12,586 12,570 6,804
Accounts Payable		 22,543 23,505 25,402 24,789 27,036 29,658 30,650 31,326 29,329 30,492 31,945
Total Noncurrent Liabilities		 94,025 92,586 91,980 93,651 90,230 89,319 86,473 99,305 93,201 94,289 93,048
Long-Term Debt		 61,002 60,399 59,135 59,292 55,812 55,631 52,194 63,805 58,048 58,509 60,340
Noncurrent Deferred & Payable Income Tax Liabilities		 2,255 1,972 2,190 2,110 2,124 2,044 1,952 2,722 2,726 2,749 2,579
Other Noncurrent Operating Liabilities		 30,768 30,215 30,655 32,249 32,294 31,644 32,327 32,778 32,427 33,031 30,129
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14,688 16,027 17,287 13,303 12,898 12,129 10,397 8,047 6,821 6,071 3,364
Total Preferred & Common Equity		 14,653 15,994 17,254 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325
Total Common Equity		 14,653 15,994 17,254 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325
Common Stock		 18,924 19,074 19,263 19,637 19,857 20,039 20,198 20,674 20,897 21,178 21,351
Retained Earnings		 3,516 4,953 4,784 2,393 1,789 933 -1,000 -2,384 -3,768 -4,964 -7,900
Treasury Stock		 -4,591 -4,590 -4,594 -6,524 -6,528 -6,525 -6,533 -7,829 -7,838 -7,848 -8,201
Accumulated Other Comprehensive Income / (Loss)		 -3,196 -3,443 -2,199 -2,232 -2,252 -2,353 -2,305 -2,454 -2,513 -2,334 -1,925
Noncontrolling Interest		 35 33 33 29 32 35 37 40 43 39 39

Annual Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 14.52% 12.16% 10.06% 16.08% 1.57% 37.69% 22.69% 3.30% -6.44% 3.71%
EBITDA Growth		 130.32% 22.91% 1.93% -20.78% 47.45% 1.65% 96.67% 0.39% -30.67% -14.25%
EBIT Growth		 165.62% 20.71% -1.33% -27.37% 56.68% -42.85% 170.75% 0.96% -48.88% -25.94%
NOPAT Growth		 128.42% 20.87% -7.01% 6.51% 73.87% 27.27% 3.11% -0.09% -37.54% 5.95%
Net Income Growth		 189.97% 15.73% -10.82% 7.12% 38.60% -41.36% 149.87% 2.56% -58.86% -12.05%
EPS Growth		 184.55% 15.97% -9.09% 10.91% 44.26% -48.48% 137.13% 2.79% -58.97% -12.13%
Operating Cash Flow Growth		 324.51% -6.56% 41.46% 34.81% -0.77% 32.00% 29.50% 9.51% -8.44% -17.66%
Free Cash Flow Firm Growth		 -486.93% 70.65% 152.22% 718.79% 86.95% -285.00% 143.10% 10.46% -9.22% -89.63%
Invested Capital Growth		 157.74% 35.32% 10.97% -20.17% -49.72% 387.52% -9.26% -13.32% -20.29% 14.14%
Revenue Q/Q Growth		 4.33% 1.57% 3.46% 1.76% 1.21% 12.68% 1.86% 0.41% -1.49% 1.44%
EBITDA Q/Q Growth		 61.15% 2.37% -7.27% -29.71% 89.65% -19.07% 30.93% -4.85% -10.41% -18.43%
EBIT Q/Q Growth		 70.49% 1.90% -8.81% -35.56% 128.29% -43.76% 59.44% -8.28% -18.92% -35.61%
NOPAT Q/Q Growth		 52.33% -0.86% -16.48% -23.71% 68.77% 44.38% -8.22% -0.83% -18.97% 6.90%
Net Income Q/Q Growth		 82.61% -2.07% -20.14% -24.82% 142.15% -37.41% 53.13% -11.72% -25.27% -16.50%
EPS Q/Q Growth		 84.12% -2.16% -19.71% 0.00% 0.00% -42.49% 58.87% -11.48% -25.89% -16.72%
Operating Cash Flow Q/Q Growth		 27.73% -5.65% 11.70% 6.40% -0.87% 9.86% 0.98% 10.42% -10.48% 13.90%
Free Cash Flow Firm Q/Q Growth		 18.52% -8.45% -75.09% 102.47% 104.98% -17.32% -18.28% 10.42% -7.97% 687.62%
Invested Capital Q/Q Growth		 -2.25% -1.12% 10.09% -14.37% -47.61% -4.01% 0.29% -3.31% -4.46% -7.07%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 80.31% 77.25% 75.04% 76.44% 77.64% 63.40% 68.96% 68.80% 60.98% 69.99%
EBITDA Margin		 35.73% 39.15% 36.26% 24.75% 35.93% 26.52% 42.52% 41.32% 30.62% 25.32%
Operating Margin		 32.97% 36.43% 33.83% 19.49% 39.03% 24.81% 31.89% 31.21% 23.49% 16.22%
EBIT Margin		 32.07% 34.52% 30.94% 19.36% 29.87% 12.40% 27.36% 26.74% 14.61% 10.43%
Profit (Net Income) Margin		 22.50% 23.22% 18.82% 17.36% 23.69% 10.09% 20.55% 20.40% 8.97% 7.61%
Tax Burden Percent		 77.41% 75.51% 68.71% 109.43% 93.54% 136.02% 88.91% 87.89% 77.97% 115.34%
Interest Burden Percent		 90.64% 89.09% 88.50% 81.96% 84.81% 59.85% 84.49% 86.83% 78.77% 63.24%
Effective Tax Rate		 22.59% 24.49% 31.29% -9.43% 6.46% -36.02% 11.09% 12.11% 22.03% -15.34%
Return on Invested Capital (ROIC)		 27.33% 19.49% 14.94% 16.82% 43.83% 28.38% 18.49% 20.80% 15.57% 17.37%
ROIC Less NNEP Spread (ROIC-NNEP)		 23.60% 16.04% 11.74% 13.81% 32.00% 7.54% 12.39% 14.03% 5.43% 5.75%
Return on Net Nonoperating Assets (RNNOA)		 153.57% 119.26% 94.16% -356.44% -138.70% 159.31% 62.46% 51.59% 19.63% 44.92%
Return on Equity (ROE)		 180.90% 138.75% 109.09% -339.62% -94.86% 187.70% 80.95% 72.40% 35.20% 62.29%
Cash Return on Invested Capital (CROIC)		 -60.86% -10.53% 4.53% 39.25% 110.01% -103.54% 28.20% 35.07% 38.16% 4.16%
Operating Return on Assets (OROA)		 18.20% 14.85% 12.76% 9.75% 13.38% 4.74% 10.35% 10.88% 5.80% 4.35%
Return on Assets (ROA)		 12.77% 9.99% 7.76% 8.74% 10.62% 3.86% 7.77% 8.30% 3.56% 3.18%
Return on Common Equity (ROCE)		 180.90% 138.75% 109.09% -339.62% -94.86% 186.90% 80.81% 72.26% 35.12% 61.95%
Return on Equity Simple (ROE_SIMPLE)		 130.39% 128.41% 104.16% -67.33% -96.45% 35.35% 74.95% 68.65% 47.04% 128.90%
Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 6,985 12,145 15,456 15,937 15,923 9,946 10,539
NOPAT Margin		 25.52% 27.51% 23.24% 21.33% 36.51% 33.74% 28.36% 27.43% 18.31% 18.71%
Net Nonoperating Expense Percent (NNEP)		 3.73% 3.45% 3.20% 3.00% 11.84% 20.84% 6.10% 6.78% 10.14% 11.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 19.77% 14.25% 14.95%
Cost of Revenue to Revenue		 19.69% 22.75% 24.96% 23.56% 22.36% 36.60% 31.04% 31.20% 39.02% 30.01%
SG&A Expenses to Revenue		 27.94% 22.94% 22.31% 22.59% 20.87% 24.67% 23.97% 26.29% 23.70% 31.08%
R&D to Revenue		 19.40% 17.88% 18.90% 32.83% 20.42% 13.93% 12.32% 11.21% 14.13% 22.71%
Operating Expenses to Revenue		 47.34% 40.82% 41.21% 56.95% 38.61% 38.59% 37.06% 37.60% 37.50% 53.77%
Earnings before Interest and Taxes (EBIT)		 7,331 8,849 8,731 6,341 9,935 5,678 15,373 15,521 7,934 5,876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 8,167 10,038 10,232 8,106 11,952 12,149 23,894 23,988 16,632 14,262
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 16.90 15.69 22.45 0.00 0.00 12.42 13.98 15.22 25.24 93.56
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.92 2.84 4.05 3.26 3.20 3.55 3.83 4.52 4.81 5.52
Price to Earnings (P/E)		 12.96 12.22 21.55 18.77 13.51 35.18 18.66 22.18 53.77 72.72
Dividend Yield		 4.95% 5.09% 3.57% 5.06% 5.94% 5.13% 4.27% 3.80% 4.00% 3.52%
Earnings Yield		 7.72% 8.18% 4.64% 5.33% 7.40% 2.84% 5.36% 4.51% 1.86% 1.38%
Enterprise Value to Invested Capital (EV/IC)		 3.04 2.64 3.37 4.12 7.19 2.65 3.44 4.45 5.43 5.76
Enterprise Value to Revenue (EV/Rev)		 4.09 4.28 5.51 4.64 4.00 5.23 5.02 5.45 5.67 6.61
Enterprise Value to EBITDA (EV/EBITDA)		 11.45 10.93 15.20 18.76 11.15 19.73 11.80 13.19 18.51 26.11
Enterprise Value to EBIT (EV/EBIT)		 12.75 12.40 17.81 23.98 13.41 42.22 18.34 20.38 38.79 63.38
Enterprise Value to NOPAT (EV/NOPAT)		 16.02 15.56 23.71 21.77 10.97 15.51 17.69 19.87 30.95 35.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.41 15.59 15.61 11.33 10.00 13.63 12.38 12.68 13.48 19.80
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 78.10 9.33 4.37 0.00 11.60 11.78 12.63 147.41
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 8.96 9.75 10.39 -6.49 -8.17 6.57 4.97 3.66 5.71 19.96
Long-Term Debt to Equity		 8.35 9.66 9.13 -5.86 -7.71 5.92 4.16 3.42 5.02 17.94
Financial Leverage		 6.51 7.44 8.02 -25.80 -4.33 21.12 5.04 3.68 3.61 7.82
Leverage Ratio		 14.17 13.89 14.06 -38.86 -8.93 48.67 10.41 8.72 9.88 19.61
Compound Leverage Factor		 12.84 12.37 12.45 -31.85 -7.58 29.12 8.80 7.57 7.78 12.40
Debt to Total Capital		 89.96% 90.70% 91.22% 118.22% 113.96% 86.79% 83.24% 78.54% 85.10% 95.23%
Short-Term Debt to Total Capital		 6.18% 0.81% 11.05% 11.45% 6.41% 8.57% 13.56% 5.13% 10.30% 9.65%
Long-Term Debt to Total Capital		 83.78% 89.89% 80.18% 106.77% 107.55% 78.22% 69.68% 73.41% 74.80% 85.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.03% 0.04% 0.05% 0.06%
Common Equity to Total Capital		 10.04% 9.30% 8.78% -18.22% -13.96% 13.19% 16.73% 21.42% 14.85% 4.72%
Debt to EBITDA		 4.33 4.50 5.18 6.76 5.58 7.08 3.21 2.64 3.57 4.71
Net Debt to EBITDA		 3.28 3.68 4.02 5.59 2.23 6.36 2.79 2.24 2.78 4.30
Long-Term Debt to EBITDA		 4.03 4.46 4.55 6.11 5.27 6.38 2.69 2.47 3.14 4.23
Debt to NOPAT		 6.06 6.41 8.08 7.85 5.49 5.57 4.81 3.97 5.97 6.37
Net Debt to NOPAT		 4.60 5.24 6.27 6.49 2.20 5.00 4.18 3.38 4.65 5.82
Long-Term Debt to NOPAT		 5.64 6.35 7.10 7.09 5.19 5.02 4.03 3.71 5.25 5.73
Altman Z-Score		 1.88 1.75 2.04 1.92 1.93 1.11 1.69 2.12 1.81 1.78
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% 0.17% 0.19% 0.25% 0.55%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.50 1.65 1.28 0.98 3.18 0.84 0.79 0.96 0.87 0.66
Quick Ratio		 1.21 1.14 0.89 0.78 2.91 0.60 0.56 0.69 0.63 0.43
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12,990 -3,813 1,991 16,303 30,479 -56,386 24,305 26,848 24,372 2,527
Operating Cash Flow to CapEx		 1,416.35% 1,469.94% 1,882.80% 2,104.55% 2,413.77% 2,204.01% 2,894.16% 3,588.92% 2,939.38% 1,930.80%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.57 0.43 0.41 0.50 0.45 0.38 0.38 0.41 0.40 0.42
Accounts Receivable Turnover		 5.40 5.40 5.73 6.26 6.15 6.43 5.98 5.47 4.85 5.10
Inventory Turnover		 3.17 3.69 4.62 4.81 4.35 6.54 5.42 5.40 5.52 4.08
Fixed Asset Turnover		 9.05 9.92 10.44 11.52 11.38 11.16 10.85 11.56 10.95 11.13
Accounts Payable Turnover		 0.58 0.65 0.72 0.70 0.63 1.05 0.81 0.75 0.76 0.54
Days Sales Outstanding (DSO)		 67.58 67.54 63.68 58.35 59.32 56.78 61.05 66.74 75.29 71.51
Days Inventory Outstanding (DIO)		 115.30 98.98 79.02 75.90 83.85 55.77 67.35 67.58 66.12 89.39
Days Payable Outstanding (DPO)		 625.25 558.33 508.08 523.92 582.97 348.29 448.33 484.70 482.68 675.79
Cash Conversion Cycle (CCC)		 -442.36 -391.81 -365.38 -389.67 -439.81 -235.74 -319.93 -350.37 -341.27 -514.89
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 30,759 41,624 46,191 36,873 18,539 90,381 82,013 71,088 56,662 64,674
Invested Capital Turnover		 1.07 0.71 0.64 0.79 1.20 0.84 0.65 0.76 0.85 0.93
Increase / (Decrease) in Invested Capital		 18,825 10,865 4,567 -9,318 -18,334 71,842 -8,368 -10,925 -14,426 8,012
Enterprise Value (EV)		 93,473 109,742 155,500 152,086 133,216 239,699 281,950 316,377 307,792 372,436
Market Capitalization		 66,659 72,754 114,406 106,767 106,505 162,394 215,345 262,543 261,490 311,087
Book Value per Share		 $2.41 $2.85 $3.19 ($5.61) ($5.53) $7.41 $8.72 $9.76 $5.87 $1.88
Tangible Book Value per Share		 ($17.70) ($24.42) ($23.96) ($30.14) ($28.69) ($58.30) ($52.56) ($46.56) ($43.92) ($51.89)
Total Capital		 39,311 49,830 58,070 46,354 58,556 99,153 92,120 80,558 69,782 70,508
Total Debt		 35,366 45,194 52,973 54,800 66,728 86,056 76,684 63,271 59,385 67,144
Total Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340
Net Debt		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310
Capital Expenditures (CapEx)		 532 479 529 638 552 798 787 695 777 974
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -556 385 1,208 -3,047 -2,237 -4,465 -4,601 -6,168 -10,464 -11,918
Debt-free Net Working Capital (DFNWC)		 7,851 6,808 10,997 5,014 37,687 4,014 5,229 3,061 2,352 -6,363
Net Working Capital (NWC)		 5,420 6,406 4,582 -294 33,934 -4,488 -7,266 -1,075 -4,839 -13,167
Net Nonoperating Expense (NNE)		 691 1,099 1,249 1,298 4,263 10,834 4,388 4,078 5,073 6,253
Net Nonoperating Obligations (NNO)		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310
Total Depreciation and Amortization (D&A)		 836 1,189 1,501 1,765 2,017 6,471 8,521 8,467 8,698 8,386
Debt-free, Cash-free Net Working Capital to Revenue		 -2.43% 1.50% 4.28% -9.30% -6.72% -9.75% -8.19% -10.62% -19.26% -21.16%
Debt-free Net Working Capital to Revenue		 34.35% 26.55% 38.97% 15.31% 113.29% 8.76% 9.30% 5.27% 4.33% -11.30%
Net Working Capital to Revenue		 23.71% 24.99% 16.24% -0.90% 102.01% -9.80% -12.93% -1.85% -8.91% -23.37%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40
Adjusted Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39
Adjusted Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.61B 1.59B 1.59B 1.48B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 4,468 12,145 7,954 15,937 15,923 9,946 6,396
Normalized NOPAT Margin		 25.52% 27.51% 23.24% 13.64% 36.51% 17.37% 28.36% 27.43% 18.31% 11.35%
Pre Tax Income Margin		 29.07% 30.75% 27.39% 15.87% 25.33% 7.42% 23.11% 23.21% 11.51% 6.60%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 64.04% 62.44% 77.36% 98.12% 80.77% 166.94% 80.19% 84.79% 216.27% 257.23%
Augmented Payout Ratio		 215.05% 164.94% 103.92% 310.08% 94.13% 188.53% 88.28% 97.34% 257.52% 299.39%

Quarterly Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 4.47% 3.28% 1.58% -9.70% -4.92% -5.97% -5.42% 0.70% 4.31% 3.83% 5.60%
EBITDA Growth		 -5.09% 10.97% -17.93% -59.37% 41.33% -35.43% -34.51% 40.12% -10.16% 3.66% -87.92%
EBIT Growth		 -3.05% 14.60% -28.93% -83.01% 78.66% -51.99% -53.79% 137.67% -13.45% 13.78% -204.34%
NOPAT Growth		 -11.98% 11.35% -4.54% -67.34% 35.60% -49.69% -52.65% 55.75% -27.02% 38.22% -148.02%
Net Income Growth		 20.68% 24.28% -38.89% -94.64% 118.43% -54.93% -66.67% 469.29% -32.26% -12.18% -102.79%
EPS Growth		 21.43% 24.16% -38.05% -94.82% 123.53% -54.75% -67.86% 492.31% -32.46% -12.00% -106.67%
Operating Cash Flow Growth		 2.35% -4.20% 46.36% -14.57% 26.25% -0.37% -36.01% -3.65% -64.06% -28.08% 48.29%
Free Cash Flow Firm Growth		 -14.91% -22.97% 17.75% 29.66% 45.54% 31.45% 7.00% -53.62% -78.89% -145.51% -154.55%
Invested Capital Growth		 -9.84% -10.10% -13.32% -16.52% -16.22% -19.33% -20.29% -6.93% -1.28% 17.35% 14.14%
Revenue Q/Q Growth		 7.72% 1.57% 2.09% -19.15% 13.42% 0.45% 2.69% -13.92% 17.48% -0.01% 4.44%
EBITDA Q/Q Growth		 -49.91% 88.53% -21.18% -45.41% 74.21% -13.86% -20.06% 16.80% 11.70% -0.61% -90.68%
EBIT Q/Q Growth		 -68.64% 185.54% -29.73% -73.00% 229.82% -23.27% -32.37% 38.87% 20.11% 0.87% -162.02%
NOPAT Q/Q Growth		 -39.89% 59.95% 10.95% -69.38% 149.57% -40.65% 4.43% 0.70% 16.94% 12.40% -136.28%
Net Income Q/Q Growth		 -79.35% 325.86% -37.45% -90.25% 741.08% -12.14% -53.73% 66.50% 0.07% 13.91% -101.47%
EPS Q/Q Growth		 -79.68% 333.33% -36.65% -90.71% 776.92% -12.28% -55.00% 71.11% 0.00% 14.29% -103.41%
Operating Cash Flow Q/Q Growth		 1.98% 51.89% -2.29% -43.55% 50.70% 19.86% -37.25% -15.00% -43.79% 139.85% 29.39%
Free Cash Flow Firm Q/Q Growth		 -4.24% 12.29% 25.18% -3.67% 7.48% 1.42% 1.90% -58.25% -51.07% -318.61% -22.15%
Invested Capital Q/Q Growth		 -5.54% -5.03% -3.31% -3.76% -5.20% -8.56% -4.46% 12.38% 0.55% 8.70% -7.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 69.56% 65.83% 70.82% 66.17% 69.42% 52.96% 56.18% 65.41% 64.47% 70.87% 78.18%
EBITDA Margin		 25.83% 47.95% 37.02% 25.00% 38.40% 32.93% 25.63% 34.78% 33.07% 32.88% 2.93%
Operating Margin		 22.59% 31.08% 36.39% 22.64% 32.55% 16.38% 22.34% 22.73% 27.64% 26.49% -9.87%
EBIT Margin		 11.76% 33.06% 22.76% 7.60% 22.10% 16.88% 11.12% 17.94% 18.34% 18.50% -10.99%
Profit (Net Income) Margin		 6.36% 26.68% 16.35% 1.97% 14.62% 12.79% 5.76% 11.15% 9.49% 10.82% -0.15%
Tax Burden Percent		 78.44% 89.82% 83.37% 50.74% 77.66% 91.19% 67.99% 78.18% 63.98% 75.05% 1.01%
Interest Burden Percent		 68.98% 89.85% 86.17% 51.13% 85.18% 83.07% 76.23% 79.48% 80.92% 77.91% 136.77%
Effective Tax Rate		 21.56% 10.18% 16.63% 49.26% 22.34% 8.81% 32.01% 21.82% 36.02% 24.95% 0.00%
Return on Invested Capital (ROIC)		 12.45% 20.78% 23.01% 8.67% 19.91% 12.40% 12.92% 14.64% 15.10% 17.13% -6.41%
ROIC Less NNEP Spread (ROIC-NNEP)		 10.01% 20.49% 19.49% 6.74% 17.33% 11.83% 10.22% 13.16% 12.92% 14.76% -4.52%
Return on Net Nonoperating Assets (RNNOA)		 49.92% 87.01% 71.71% 27.49% 72.05% 43.97% 36.95% 68.28% 71.55% 89.80% -35.31%
Return on Equity (ROE)		 62.37% 107.80% 94.71% 36.16% 91.96% 56.37% 49.86% 82.92% 86.65% 106.93% -41.72%
Cash Return on Invested Capital (CROIC)		 29.50% 31.31% 35.07% 36.10% 37.98% 39.88% 38.16% 22.62% 15.71% -0.67% 4.16%
Operating Return on Assets (OROA)		 4.63% 13.17% 9.26% 3.10% 8.89% 6.71% 4.42% 6.89% 7.27% 7.35% -4.59%
Return on Assets (ROA)		 2.51% 10.63% 6.65% 0.81% 5.88% 5.08% 2.29% 4.28% 3.77% 4.30% -0.06%
Return on Common Equity (ROCE)		 62.23% 107.58% 94.54% 36.09% 91.74% 56.24% 49.74% 82.65% 86.32% 106.49% -41.49%
Return on Equity Simple (ROE_SIMPLE)		 86.30% 83.89% 0.00% 57.20% 67.56% 53.92% 0.00% 74.98% 78.93% 85.10% 0.00%
Net Operating Profit after Tax (NOPAT)		 2,585 4,134 4,587 1,404 3,505 2,080 2,172 2,187 2,558 2,875 -1,043
NOPAT Margin		 17.72% 27.91% 30.34% 11.49% 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91%
Net Nonoperating Expense Percent (NNEP)		 2.44% 0.29% 3.51% 1.93% 2.58% 0.57% 2.69% 1.47% 2.17% 2.37% -1.90%
Return On Investment Capital (ROIC_SIMPLE)		 - - 5.69% - - - 3.11% - - - -1.48%
Cost of Revenue to Revenue		 30.44% 34.18% 29.18% 33.83% 30.58% 47.04% 43.82% 34.59% 35.53% 29.13% 21.82%
SG&A Expenses to Revenue		 37.11% 22.31% 22.60% 24.86% 25.59% 24.21% 20.37% 26.93% 23.35% 29.65% 43.24%
R&D to Revenue		 11.03% 10.90% 11.84% 18.75% 12.50% 12.37% 13.47% 15.75% 13.47% 14.73% 44.86%
Operating Expenses to Revenue		 46.97% 34.75% 34.43% 43.53% 36.87% 36.58% 33.84% 42.68% 36.82% 44.38% 88.05%
Earnings before Interest and Taxes (EBIT)		 1,715 4,897 3,441 929 3,064 2,351 1,590 2,208 2,652 2,675 -1,659
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3,767 7,102 5,598 3,056 5,324 4,586 3,666 4,282 4,783 4,754 443
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.93 13.73 15.22 20.04 17.59 20.78 25.24 39.42 44.28 57.37 93.56
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.33 3.80 4.52 4.69 4.04 4.56 4.81 5.80 5.46 6.23 5.52
Price to Earnings (P/E)		 19.63 16.38 22.18 35.08 26.06 38.58 53.77 52.67 56.21 67.56 72.72
Dividend Yield		 3.86% 4.45% 3.80% 3.80% 4.51% 4.11% 4.00% 3.35% 3.57% 3.13% 3.52%
Earnings Yield		 5.09% 6.11% 4.51% 2.85% 3.84% 2.59% 1.86% 1.90% 1.78% 1.48% 1.38%
Enterprise Value to Invested Capital (EV/IC)		 4.02 3.77 4.45 4.70 4.29 5.03 5.43 5.83 5.58 5.89 5.76
Enterprise Value to Revenue (EV/Rev)		 5.42 4.79 5.45 5.66 4.97 5.41 5.67 6.82 6.50 7.38 6.61
Enterprise Value to EBITDA (EV/EBITDA)		 12.68 10.99 13.19 16.45 13.20 16.08 18.51 20.79 20.64 23.43 26.11
Enterprise Value to EBIT (EV/EBIT)		 19.07 16.37 20.38 29.25 22.57 30.51 38.79 40.30 40.61 44.89 63.38
Enterprise Value to NOPAT (EV/NOPAT)		 19.89 17.26 19.87 23.61 19.25 24.32 30.95 36.42 38.46 41.55 35.34
Enterprise Value to Operating Cash Flow (EV/OCF)		 13.56 12.27 12.68 13.26 10.90 11.70 13.48 16.37 19.17 24.81 19.80
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.91 11.40 11.78 11.83 10.30 11.27 12.63 24.85 35.30 0.00 147.41
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 4.97 4.34 3.66 4.67 4.73 5.01 5.71 9.20 10.36 11.71 19.96
Long-Term Debt to Equity		 4.15 3.77 3.42 4.46 4.33 4.59 5.02 7.93 8.51 9.64 17.94
Financial Leverage		 4.98 4.25 3.68 4.08 4.16 3.72 3.61 5.19 5.54 6.08 7.82
Leverage Ratio		 10.67 9.80 8.72 9.38 10.10 9.86 9.88 13.27 14.06 15.37 19.61
Compound Leverage Factor		 7.36 8.81 7.51 4.80 8.60 8.19 7.53 10.55 11.38 11.97 26.82
Debt to Total Capital		 83.24% 81.28% 78.54% 82.36% 82.55% 83.36% 85.10% 90.19% 91.19% 92.13% 95.23%
Short-Term Debt to Total Capital		 13.62% 10.75% 5.13% 3.72% 7.04% 7.02% 10.30% 12.43% 16.25% 16.29% 9.65%
Long-Term Debt to Total Capital		 69.62% 70.53% 73.41% 78.64% 75.51% 76.34% 74.80% 77.77% 74.94% 75.84% 85.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.04% 0.04% 0.04% 0.04% 0.04% 0.05% 0.05% 0.05% 0.06% 0.05% 0.06%
Common Equity to Total Capital		 16.72% 18.68% 21.42% 17.61% 17.41% 16.60% 14.85% 9.76% 8.75% 7.82% 4.72%
Debt to EBITDA		 2.98 2.76 2.64 3.18 2.89 3.27 3.57 4.14 4.08 4.07 4.71
Net Debt to EBITDA		 2.56 2.28 2.24 2.82 2.46 2.54 2.78 3.12 3.30 3.63 4.30
Long-Term Debt to EBITDA		 2.49 2.40 2.47 3.04 2.65 3.00 3.14 3.57 3.35 3.35 4.23
Debt to NOPAT		 4.67 4.34 3.97 4.56 4.22 4.95 5.97 7.26 7.60 7.21 6.37
Net Debt to NOPAT		 4.01 3.58 3.38 4.05 3.59 3.84 4.65 5.46 6.16 6.44 5.82
Long-Term Debt to NOPAT		 3.90 3.76 3.71 4.36 3.86 4.53 5.25 6.26 6.25 5.94 5.73
Altman Z-Score		 1.59 1.60 1.84 1.78 1.59 1.67 1.65 1.72 1.68 1.78 1.59
Noncontrolling Interest Sharing Ratio		 0.22% 0.20% 0.19% 0.20% 0.24% 0.24% 0.25% 0.32% 0.38% 0.41% 0.55%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.84 0.93 0.96 0.96 0.89 0.96 0.87 0.94 0.81 0.65 0.66
Quick Ratio		 0.61 0.69 0.69 0.66 0.63 0.71 0.63 0.72 0.59 0.44 0.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11,036 12,392 15,512 14,943 16,061 16,289 16,598 6,930 3,391 -7,413 -9,055
Operating Cash Flow to CapEx		 3,500.00% 4,294.92% 3,487.32% 2,396.00% 3,550.00% 3,458.45% 2,318.54% 2,093.26% 942.32% 2,187.55% 2,421.99%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 0.40 0.41 0.41 0.40 0.40 0.40 0.38 0.40 0.40 0.42
Accounts Receivable Turnover		 5.42 5.78 5.47 5.11 4.93 4.98 4.85 4.65 4.74 4.85 5.10
Inventory Turnover		 5.06 5.69 5.40 4.93 4.79 5.41 5.52 5.28 5.37 4.71 4.08
Fixed Asset Turnover		 11.33 11.54 11.56 11.34 11.32 11.22 10.95 10.98 11.04 11.02 11.13
Accounts Payable Turnover		 0.79 0.79 0.75 0.76 0.72 0.73 0.76 0.76 0.79 0.66 0.54
Days Sales Outstanding (DSO)		 67.31 63.20 66.74 71.42 74.04 73.33 75.29 78.57 77.03 75.20 71.51
Days Inventory Outstanding (DIO)		 72.12 64.13 67.58 73.97 76.18 67.50 66.12 69.16 67.97 77.42 89.39
Days Payable Outstanding (DPO)		 460.75 464.27 484.70 478.83 506.87 501.67 482.68 480.46 463.07 552.32 675.79
Cash Conversion Cycle (CCC)		 -321.32 -336.94 -350.37 -333.43 -356.66 -360.84 -341.27 -332.72 -318.07 -399.70 -514.89
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 77,415 73,519 71,088 68,417 64,859 59,310 56,662 63,674 64,026 69,598 64,674
Invested Capital Turnover		 0.70 0.74 0.76 0.75 0.79 0.83 0.85 0.82 0.85 0.86 0.93
Increase / (Decrease) in Invested Capital		 -8,451 -8,258 -10,925 -13,539 -12,556 -14,209 -14,426 -4,743 -833 10,288 8,012
Enterprise Value (EV)		 310,864 277,087 316,377 321,218 278,344 298,520 307,792 371,297 357,373 409,620 372,436
Market Capitalization		 248,102 219,562 262,543 266,075 226,351 251,304 261,490 315,630 300,125 346,054 311,087
Book Value per Share		 $8.29 $9.05 $9.76 $7.50 $7.29 $6.85 $5.87 $4.53 $3.84 $3.42 $1.88
Tangible Book Value per Share		 ($50.48) ($47.77) ($46.56) ($47.36) ($46.60) ($44.53) ($43.92) ($49.54) ($49.18) ($54.30) ($51.89)
Total Capital		 87,620 85,633 80,558 75,396 73,913 72,875 69,782 82,048 77,455 77,150 70,508
Total Debt		 72,932 69,606 63,271 62,093 61,015 60,746 59,385 74,001 70,634 71,079 67,144
Total Long-Term Debt		 61,002 60,399 59,135 59,292 55,812 55,631 52,194 63,805 58,048 58,509 60,340
Net Debt		 62,727 57,492 53,801 55,114 51,961 47,181 46,265 55,627 57,205 63,527 61,310
Capital Expenditures (CapEx)		 143 177 213 175 178 219 205 193 241 249 291
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3,404 -5,020 -6,168 -5,023 -6,950 -9,724 -10,464 -10,524 -8,670 -9,992 -11,918
Debt-free Net Working Capital (DFNWC)		 6,557 6,859 3,061 1,699 1,816 3,566 2,352 7,545 4,487 -2,707 -6,363
Net Working Capital (NWC)		 -5,373 -2,348 -1,075 -1,102 -3,387 -1,549 -4,839 -2,651 -8,099 -15,277 -13,167
Net Nonoperating Expense (NNE)		 1,657 182 2,115 1,163 1,478 299 1,348 815 1,185 1,311 -1,020
Net Nonoperating Obligations (NNO)		 62,727 57,492 53,801 55,114 51,961 47,181 46,265 55,627 57,205 63,527 61,310
Total Depreciation and Amortization (D&A)		 2,052 2,205 2,157 2,127 2,260 2,235 2,076 2,074 2,131 2,079 2,102
Debt-free, Cash-free Net Working Capital to Revenue		 -5.94% -8.68% -10.62% -8.85% -12.41% -17.64% -19.26% -19.34% -15.76% -17.99% -21.16%
Debt-free Net Working Capital to Revenue		 11.43% 11.86% 5.27% 2.99% 3.24% 6.47% 4.33% 13.87% 8.16% -4.87% -11.30%
Net Working Capital to Revenue		 -9.37% -4.06% -1.85% -1.94% -6.05% -2.81% -8.91% -4.87% -14.73% -27.51% -23.37%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.52 $2.22 $1.39 $0.13 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02)
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $0.51 $2.21 $1.40 $0.13 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 1.78B 1.78B 1.78B 1.78B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.76B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 2,585 4,134 4,587 1,404 3,505 2,080 2,172 2,187 2,558 2,875 -1,043
Normalized NOPAT Margin		 17.72% 27.91% 30.34% 11.49% 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91%
Pre Tax Income Margin		 8.11% 29.71% 19.61% 3.89% 18.82% 14.02% 8.47% 14.26% 14.84% 14.41% -15.02%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 76.40% 73.42% 84.79% 134.04% 118.45% 159.78% 216.27% 177.38% 201.40% 212.33% 257.23%
Augmented Payout Ratio		 89.18% 85.44% 97.34% 160.02% 141.15% 190.03% 257.52% 200.35% 227.16% 239.43% 299.39%

Key Financial Trends

AbbVie’s financial results over the past four years reveal several important trends in its revenue, profitability, operating expenses, and balance sheet strength. Below is a summary highlighting the key points that retail investors should consider.

  • Revenue growth has been generally strong, with total revenue increasing from approximately $13.5 billion in Q1 2021 to over $15 billion by Q4 2024, reflecting steady business expansion.
  • Gross profit margins have remained robust, with gross profit around $10 to $11 billion in recent quarters, supporting strong core profitability despite a challenging cost environment.
  • Operating cash flow remains healthy, with consistent positive net cash from operating activities each quarter, reaching about $7 billion in the latest quarter ending Q4 2024.
  • AbbVie maintains a strong intangible asset base (~$60 billion) and goodwill (~$35 billion), indicating significant investment in its product portfolio and acquisitions to drive future growth.
  • Net income showed volatility, with AbbVie reporting losses in Q4 2024 (-$23 million), a sharp contrast to the strong positive earnings in prior quarters, which may indicate unusual expenses or write-offs in that quarter.
  • Operating expenses, particularly research and development (R&D), have increased considerably in recent quarters, spiking to over $6.7 billion in Q4 2024, more than doubling compared to earlier periods, which weighs on operating income.
  • Total liabilities have risen over time, reaching approximately $132 billion by the end of 2024, which reflects increased debt and financial obligations from acquisitions and operations.
  • AbbVie’s equity value fluctuated but remained positive, with total shareholders’ equity around $3.3 billion at the end of 2024, despite some declines from prior years.
  • Dividend payments remain a consistent use of cash, around $2.7 billion each quarter, suggesting a commitment to returning value to shareholders despite recent profitability pressures.
  • Cash & cash equivalents decreased from about $18 billion in Q1 2024 to $5.5 billion in Q4 2024, indicating cash usage, likely related to debt repayments and increased investments.

Summary: AbbVie has demonstrated strong revenue growth and solid cash flow generation over recent years, supported by its sizable asset base and strategic investments. However, the significant rise in R&D and operating expenses, along with the reported net loss in Q4 2024, flags some near-term profitability challenges. The company’s rising debt load and shrinking cash reserves warrant monitoring. Investors should watch for AbbVie’s ability to translate its heavy R&D spending into new successful products to sustain long-term growth and earnings stability.

08/02/25 10:18 PMAI Generated. May Contain Errors.

Frequently Asked Questions About AbbVie's Financials

When does AbbVie's fiscal year end?

According to the most recent income statement we have on file, AbbVie's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AbbVie's net income changed over the last 9 years?

AbbVie's net income appears to be on an upward trend, with a most recent value of $4.29 billion in 2024, falling from $5.14 billion in 2015. The previous period was $4.87 billion in 2023. Find out what analysts predict for AbbVie in the coming months.

What is AbbVie's operating income?
AbbVie's total operating income in 2024 was $9.14 billion, based on the following breakdown:
  • Total Gross Profit: $39.43 billion
  • Total Operating Expenses: $30.29 billion
How has AbbVie's revenue changed over the last 9 years?

Over the last 9 years, AbbVie's total revenue changed from $22.86 billion in 2015 to $56.33 billion in 2024, a change of 146.4%.

How much debt does AbbVie have?

AbbVie's total liabilities were at $131.80 billion at the end of 2024, a 6.0% increase from 2023, and a 168.4% increase since 2015.

How much cash does AbbVie have?

In the past 9 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.52 billion as of their latest financial filing in 2024.

How has AbbVie's book value per share changed over the last 9 years?

Over the last 9 years, AbbVie's book value per share changed from 2.41 in 2015 to 1.88 in 2024, a change of -22.0%.


Related Companies

This page (NYSE:ABBV) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners
I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...
Timothy Sykes | Sponsored
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsored
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsored
Alien rocks potentially worth trillions…
It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...
Porter & Company | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsored
Why AMZN, GOOG, MSFT might destroy NVDA
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...
InvestorPlace | Sponsored
Strange twist to Bitcoin’s rally
The #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...
Stansberry Research | Sponsored